Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Study presented at ESMO Breast 2025 finds specific gut bacteria and microbial enzymes may be linked to breast cancer ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

This reduces the risk of local recurrence significantly. Newer targeted therapies have emerged despite TNBC’s lack of the three common receptors. These include PARP inhibitors for patients with ...

High grade tumors: Most cases are high grade tumors; very few are low grade and those are more conservative than TNBC. Early recurrence: The risk of recurrence in TNBC peaks within the first 3 ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer ... of invasive breast cancer, recurrence elsewhere in the body ...

often facing a higher risk of recurrence and lower survival rates. However, a recent breakthrough in research and treatment is bringing newfound hope to those affected by TNBC. Advances in ...

ctDNA was most frequently detected within six months post-treatment, aligning with TNBC's early recurrence pattern. Exploratory analysis suggested longer recurrence-free intervals in patients with low ...

These cases of early recurrence meant that the hypothesis ... be started early in the course of disease for patients with TNBC, perhaps before the end of neoadjuvant therapy, especially ...